INTRODUCTION

Mycoplasma pneumoniae pneumonia, as an interstitial pneumonia caused by mycoplasma pneumoniae infection, is one of the most common respiratory infections in clinical practice, with an increasing incidence year by year.\(^1\) Macrolide antibiotics are currently the preferred treatment drugs for refractory mycoplasma pneumoniae pneumonia...
pneumonia (RMPP). However, with the increase of mycoplasma resistance to macrolide antibiotics, conventional macrolide antibiotics alone have poor efficacy in the treatment of RMPP.\textsuperscript{4,5} Budesonide, a non-halogenated glucocorticoid, can reduce vascular permeability, inhibit secretion of mucus, and relieve edema and spasm. Budesonide which is inhaled after nebulization can spread to the whole lung and is highly effective to local inflammation.\textsuperscript{6} In recent years, with the maturity of bronchoscopy technology, the therapeutic value of alveolar lavage on infected sites has been widely recognized.\textsuperscript{7} Budesonide suspension is touted to have a repair effect on inflammatory airway injury tissues, with little systemic effect and high safety.\textsuperscript{8} Local administration of budesonide after bronchoscopic alveolar lavage may achieve better efficacy. In this study, the clinical efficacy of bronchofiberscopic lavage combined with budesonide suspension in the treatment of RMPP was investigated, and adverse reactions were observed.

**METHODS**

A total of 108 children with RMPP from June 2018 to October 2020 were randomly divided into two groups: the study group and the control group, with 54 cases in each group. Among all the children, there were 32 males and 22 females in the study group, aged 1-12 years, with an average of 7.84±2.16 years. Their body temperature ranged from 37.5-39.8°C, with an average temperature of 38.44±0.73°C, and the course of disease ranged from 7-14d, with an average course of 9.69±1.24d. In the control group, there were 30 males and 24 females, aged 1-14 years, with an average of 7.95±2.33 years. Their body temperature ranged from 37.8-39.7°C, with an average temperature of 38.37±0.82°C, and the course of disease ranged from 8-15d, with an average course of 9.88±1.36. No statistically significant difference was observed in the general information of the two groups (P>0.05).

RMPP was defined as: (1) sputum culture, serum etiology and lung CT suggested mycoplasma pneumoniae pneumonia in children; (2) a sustained fever for 7 days or more and; (3) increasingly severe cough and infiltrates on chest radiographs despite the administration of appropriate macrolide antibiotics.

**Ethical Approval:** The study was approved by the Institutional Ethics Committee of Baoding First Central Hospital at March 10, 2021 (No.2021.3.10), and written informed consent was obtained from all participants.

**Inclusion criteria:**
- Children who meet the diagnostic criteria for RMPP by imaging examination and laboratory-related instrumental examinations;\textsuperscript{9}
- Children aged 1-14 years;
- Children whose family members signed the informed consent and approved by the ethics committee of the hospital.

**Exclusion criteria:**
- Children who are allergic to the drugs used in this study;
- Children with hereditary blood diseases and mental diseases;
- Children with pulmonary neoplasms or non-infectious interstitial pulmonary diseases;
- Children with a past history of bronchial asthma, immunodeficiency disease, recurrent respiratory infections, and tuberculosis infectious diseases;
- Children with fungal infection;
- Children with severe malnutrition and debilitating physical conditions.

Children in the control group were given conventional treatment, including symptomatic treatment measures such as expectoration, oxygen inhalation, respiratory support, nutritional support, and postural drainage, and were treated with the following drugs for fourteen days according to the sputum culture drug sensitivity test and serum pathogen detection, such as macrolide antibiotic intravenous drip anti-infection, 10mg/(kg·d) azithromycin (Northeast Pharmaceutical Group Shenyang No.1 Pharmaceutical Co., Ltd., State Drug Approval No.: H20000426), 80-160 mg/(kg·d) cephalosporin antibiotic - cefotiam hydrochloride (Hainan Quanxing Pharmaceutical Co., Ltd., State Drug Approval No.: H20113468), or 30-100 mg/(kg·d) cefuroxime sodium (Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd., State Drug Approval No.: H20065670) or intravenous infusion of 50-100 mg/(kg·d) cephalosporin sodium (Hainan Huluwa Pharmaceutical Group Co., Ltd., National Drug Approval: H20064990), and nebulized budesonide suspension (AstraZeneca Pharmaceutical Co., Ltd., State Drug Approval No.: H20140475). All drugs given without sputum examination or any other serological test? Quinolones can be an alternative medication; Mycoplasma is generally resistant to beta Lactam.

For children in the study group, on the basis of the treatment regimen of the control group. The children were fasted for four to six hour before surgery, and were given lidocaine spray anesthesia in nasal
cavity and pharynx 30 minutes before surgery, and the total amount of medication should be controlled within 5-7mg/kg. During the operation, the child was supine, one side of the nasal cavity was inhaled with high concentration of oxygen through the nasal catheter. And the front end of the fibrous bronchus was lubricated and slowly entered the other side of the nasal cavity, then bronchoalveolar lavage was performed. The sputum of the affected lung segment and leaf was sucked up. The saline at 37°C was infused with a perfusion volume of 5-10ml for each segment of the bronchus. After the infusion, suction was performed with negative pressure, and the pulmonary bronchus in the infected area was flushed 3-4 times each time, with the total amount of perfusion normal saline not more than 5ml/kg. Then budesonide suspension was injected into the lesion site. The treatment time of the study group was the same as that of the control group.

Observation Indexes

Criteria for curative effect: After 10d of treatment, the therapeutic effect was evaluated, and the clinical efficacy was divided into four grades: cured, markedly effective, effective and ineffective. Cured: The children’s body temperature returned to normal, lung rales and symptoms disappeared completely, and the lung lesions were 95% absorbed by X-ray examination. Markedly effective: The temperature of the children was normal, the pulmonary symptoms and lung rales basically disappeared, and the lung lesions were 90% absorbed by X-ray examination. Effective: The temperature of the children dropped by more than 1°C, symptoms were alleviated, lung rales were significantly reduced, lung lesions were 80% absorbed by X-ray examination, and inflammation absorption and lesion abnormality were effectively improved. Ineffective: The children’s high fever did not retreat, the symptoms worsened, the X-ray review changed by 20%, or even worsened.

(2) Blood gas indexes were analyzed before and after treatment, and arterial partial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2) and arterial oxygen saturation (SaO2) were measured. (3) Before and after treatment, 3ml of fasting peripheral venous blood was collected, and anticoagulant blood was collected in an EDTA vacuum. Centrifugation was carried out in a high-speed refrigerated centrifuge at room temperature at 3000r/min for 15 minutes. After serum separation, the levels of interleukin-6 (IL-6), interleukin-4 (IL-4) and interferon γ (IFN-γ) were detected by double antibody sandwich enzyme-linked immunosorbent assay. (4) The improvement of clinical symptoms and signs in the two groups were counted, including the antipyretic time, antitussive time, lung rales disappearance time and total length of hospital stay. (5) The incidence of adverse reactions in the two groups during treatment was observed.

Statistical Analysis SPSS23.0 was used for data statistics and analysis. Measurement data were expressed by mean and standard deviation and analyzed by t test; Count data were expressed by frequency and rate and analyzed by chi-square test. P<0.05 indicates a statistically significant difference.

RESULTS

The effective rate of treatment for children in the study group was 85.19%, which was higher than 66.67% in the control group (P<0.05). Table-I. The level of PaO2 in the two groups was higher than that before treatment, and that in the study group was higher than that in the control group, with a statistically significant difference (P<0.05). The levels of PaCO2 and SaO2 in the two groups were lower than before treatment, and that in the study group was higher than that in the control group, with a statistically significant difference (P<0.05). Table-II. The levels of IL-6, IL-4, and IFN-γ in the two groups after treatment were lower than those before treatment, and that in the study group was lower than that in the control group, with a statistically significant difference (P<0.05). Table-III. The antipyretic time, antitussive time, lung rales disappearance

| Group          | n  | Cured | Markedly effective | Effective | Ineffective | Effective rate (n, %) |
|----------------|----|-------|--------------------|-----------|-------------|---------------------|
| Study group    | 54 | 21    | 17                 | 8         | 8           | 46 (85.19)          |
| Control group  | 54 | 13    | 11                 | 12        | 18          | 36 (66.67)          |
| X²             |    |       |                    |           |             | 5.066               |
| P              |    |       |                    |           |             | 0.024               |
time and length of hospital stay in the study group were all shorter than those in the control group, with statistically significant differences (P<0.05). Table-IV. No statistically significant difference was observed in the incidence of adverse reactions between the two groups (P>0.05). Table-V.

Table-III: Changes in the levels of IL-6, IL-4 and IFN-γ between the two groups (X±s).

| Group                  | IL-6 (pg/ml) | IL-4 (pg/ml) | IFN-γ (pg/ml) |
|------------------------|--------------|--------------|---------------|
|                        | Before       | After        | Before        | After        | Before        | After        |
|                        | treatment    | treatment    | treatment     | treatment    | treatment     | treatment    |
| Study group (n=54)     | 39.57±5.73   | 12.35±2.03   | 102.96±18.54  | 55.21±10.02  | 192.98±17.25  | 110.21±15.32 |
| Control group (n=54)   | 40.06±5.86   | 19.78±1.96   | 103.87±19.25  | 79.86±11.05  | 193.65±13.84  | 149.76±11.02 |
| t                      | 0.439        | 0.250        | 0.223         | 0.824        |
| P                      | <0.001       | <0.001       | <0.001        | <0.001       |

Table-IV: Improvement time of clinical symptoms and signs in the two groups (X±s, d).

| Group                  | Antipyretic time | Antitussive time | Lung rales disappearance time | Length of hospital stay |
|------------------------|------------------|------------------|-------------------------------|-------------------------|
| study group (n=54)     | 2.59±0.58        | 5.63±2.07        | 4.75±1.52                    | 7.98±2.26               |
| Control group (n=54)   | 3.47±0.68        | 7.54±2.38        | 6.25±1.57                    | 9.83±3.45               |
| t                      | 7.235            | 4.450            | 5.044                         | 3.296                   |
| P                      | <0.001           | <0.001           | <0.001                        | 0.001                   |

Table-V: Occurrence of adverse reactions in the two groups during treatment.

| Group                  | Sinus Tachycardia | Decreased blood Oxygen Saturation | Vomiting | Gastrointestinal Reaction | Total Incidence n(%) |
|------------------------|-------------------|----------------------------------|----------|--------------------------|----------------------|
| Study group (n=54)     | 2                 | 1                                | 1        | 1                        | 5 (9.26)             |
| Control group (n=54)   | 1                 | 0                                | 2        | 1                        | 4 (7.41)             |
| X²                    |                   |                                  |          |                          | 0.121                |
| p                     |                   |                                  |          |                          | 0.728                |

**DISCUSSION**

In recent years, the number of refractory or severe cases of mycoplasma pneumoniae pneumonia has increased gradually, with the clinical characteristics of rapid onset, fast progress and relatively
migratory courses. Its clinical symptoms range from persistent high fever and cough to reduced breathing sounds with or without rales, and its pulmonary imaging is manifested as large-scale high-density consolidation.11-13

Antibiotic anti-infective therapy is the preferred routine treatment for mycoplasma infection. However, strain resistance has been enhanced owing to the massive use of antibiotics at the present stage, resulting in the failure of conventional anti-infective treatments to achieve the desired effect, and the slow recovery of clinical symptoms in children.14-16 Budesonide suspension is a glucocorticoid with potent topical anti-inflammatory effects that can enhance the stability of the lysosomal membrane of endothelial cells and smooth muscle cells, inhibit immune response and reduce antibody synthesis. In this way, the release of allergic active mediators such as histamine can be reduced, the activity can be inhibited, the enzymatic process triggered by the binding of antigen and antibody can be reduced, and the synthesis and release of broncho-constrictive substances can be inhibited, thereby reducing the contraction response of smooth muscles, diminishing the leakage of capillaries, exerting a strong local anti-inflammatory effect, inhibiting the hyperresponsiveness of the airway, reducing the secretion of glands, relieving symptoms, and repairing damaged airways.17-19 Bronchofiberscopy and alveolar lavage are non-invasive methods developed in recent years. With a soft texture, small lumen and strong light conduction ability, the bronchofiberscope can be easily penetrated into the airway of children, so as to facilitate the observation of the trachea or the opening of the left and right lobes of bronchus and the mucosa. Single or multiple alveolar lavage by bronchoalveolar lavage (BAL) can effectively remove inflammatory secretions of the respiratory tract in children. In combination with antibiotic drugs, mucosal edema in children can be significantly reduced, sputum dissolution can be promoted, and topical anti-inflammatory effect can be intensified, so as to ameliorate clinical symptoms of children.20

In this study, budesonide suspension combined with bronchofiberscopic lavage significantly improved the clinical efficacy of RMPP. Studies have shown that the use of intratracheal corticosteroids can not only recruit the lungs, but also alleviate pulmonary inflammation in severe respiratory distress syndrome, which provides support for our study.21 Marraro et al. found that children with bronchoalveolar lavage could improve oxygenation in the trachea of children and relieve airway obstruction. The children treated with budesonide suspension combined with bronchofiberscopic lavage had significantly shorter antipyretic time, antitussive time, lung rales disappearance time and length of hospital stay than those treated with conventional treatment, and their conditions were effectively controlled and clinical symptoms were significantly improved, which was supported by the study results of Tan et al.23 There was no significant difference in the incidence of adverse reactions between the two groups during treatment, indicating the high safety of budesonide suspension combined with bronchofiberscopic lavage.

It has been shown in studies24 that the expressions of inflammatory factors such as IL-6, IL-4 and IFN-γ in serum of children with RMPP were up-regulated, lymphocytes in infected sites were reduced, neutrophils were increased, and local reactions were aggravated. IL-4 can activate the synthesis of immune proteins, leading to wheezing attacks. IL-6 is a multifunctional cytokine, which has a close bearing on the immune response and the regulation and defense function of the hematopoietic system. It is positively correlated with the severity of infection and inflammation, and is involved in the process of pneumonia infection. IFN-γ is mainly produced by Th1 cells and is involved in regulating the immune function of the body after infection, and can mediate the production of other inflammatory mediators.25 Budesonide suspension combined with bronchofiberscopic lavage has been touted for various benefits, such as blocking the release of inflammatory mediators and cytokines, significantly reducing serum IL-6, IL-4, and IFN-γ levels in children with RMPP, diminishing airway inflammation caused by abnormal immune responses, and improving respiratory symptoms in children.

Limitations of the study: There are still some shortcomings in this study. First of all, the number of subjects included in this study is limited, so the conclusions drawn may not be very convincing. In addition, we should have set up a control group of conventional treatment combined with bronchofib-
eroscopic lavage with normal saline alone to make the findings more definitive and convincing.

CONCLUSION

Budesonide suspension combined with bronchofiberscopic lavage is a safe treatment regimen that can significantly improve the clinical efficacy of children with RMPP. With such a combined treatment regimen, the clinical symptoms of children can be ameliorated, the ventilation function can be enhanced, and the level of inflammatory mediators will be reduced.

Source of funding: None

Conflicts of interest: None

REFERENCES

1. Lee E, Young Lee Y. Risk factors for the development of post-infectious bronchiolitis obliterans after Mycoplasma pneumoniae pneumonia in the era of increasing macrolide resistance. Respir Med. 2020;175:106209. doi: 10.1016/j.rmed.2020.106209

2. Wang Z, Yang L, Ye J, Wang Y, Liu Y. Monocyte subsets study in children with Mycoplasma pneumoniae pneumonia. Immunol Res. 2019;67(4-5):373-381. doi: 10.1007/s12026-019-09066-6

3. Lan Y, Li S, Yang D, Zhou J, Wang Y, Wang J, et al. Clinical characteristics of Kawasaki disease complicated with Mycoplasma pneumoniae pneumonia: A retrospective study. Medicine (Baltimore). 2020;99(19):e19987. doi: 10.1097/MD.0000000000019987

4. Qiu JL, Huang L, Shao MV, Chai YN, Zhang HJ, Li XF, et al. Efficacy and safety of azithromycin combined with glucocorticoid on refractory Mycoplasma pneumoniae pneumonia in children: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2020;99(22):e20211. doi: 10.1097/MD.0000000000020212

5. Wang L, Wang W, Sun JM, Ni SW, Ding JL, Zhu YL, et al. Efficacy of fiberoptic bronchoscopy and bronchoalveolar lavage in childhood-onset, complicated plastic bronchitis. Pediatr Pulmonol. 2020;55(11):3088-3095. doi: 10.1002/ppul.25016

6. Li B, Han S, Liu F, Kang L, Xv C. Budesonide Nebulization in the Treatment of Neonatal Ventilator Associated Pneumonia. Pak J Med Sci. 2017;33(4):997-1001. doi: 10.2669/pjms.33.12907

7. Wang LP, Chen SP, Huang YY, Qin FF, Ou W, Liu HD, et al. Application of flexible bronchoscopy in children with respiratory diseases. Zhongguo Dang Dai Er Ke Za Zhi. 2017;19(11):1174-1179. doi: 10.7499/jzddke.2017.11.010

8. Israel S, Kumar A, DeAngelis K, Aurivillius M, Dorinsky P, Roche N, et al. Pulmonary deposition of budesonide/glucopyronium/formoterol fumarate dihydrate metered dose inhaler formulated using co-suspension delivery technology in healthy male subjects. Eur J Pharm Sci. 2020;153:105472. doi: 10.1016/j.ejps.2020.105472

9. Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011;66(Suppl 2):ii1-23. doi: 10.1136/thoraxjnl-2011-200898

10. Miyashita N, Narita M, Tanaka T, Akahei K, Teranishi H, Oishi T, et al. Histological findings in severe Mycoplasma pneumoniae pneumonia. J Med Microbiol. 2017;66(Suppl 2):ii1-23. doi: 10.1099/jmm.0.000501

11. Li G, Fan L, Wang Y, Huang L, Wang M, Zhu C, et al. High co-expression of TNF-a and CARDS toxin is a good predictor for refractory Mycoplasma pneumoniae pneumonia. Mol Med. 2019;25(1):38. doi: 10.1186/s12020-019-0105-2

12. Alishash AS, Atkinson TP, Schlappi C, Leal SM Jr, Waites KB, Xiao L. Mycoplasma pneumoniae Cartilage With De Novo Macrolide-Resistance and Breakthrough Pneumonia. Pediatrics. 2019;144(4):e20191642. doi: 10.1542/peds.2019-1642

13. Li HN, Zhao X, Zha YJ, Du F, Liu J, Sun L. miR-146a-5p suppresses ATP-binding cassette subfamily G member 1 dysregulation in patients with refractory Mycoplasma pneumoniae via interleukin-1 receptor-associated kinase 1 downregulation. Int J Mol Sci. 2019;20(4):2003-2014. doi: 10.3390/ijms2019.4380

14. Yyan C, Xue G, Zhao H, Feng Y, Li S, Cui J, et al. Molecular and clinical characteristics of severe Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol. 2019;54(7):1012-1021. doi: 10.1002/ppul.24327

15. Tamiy Y, Yoshikawa E, Ogura M, Kuroda E, Suzuki K, Yoshioka Y. Vaccination using inactivated Mycoplasma pneumoniae induces detrimental infiltration of neutrophils after subsequent infection in mice. Vaccine. 2020;38(32):4979-4987. doi: 10.1016/j.vaccine.2020.05.074

16. Gise R, Elhusseiny AM, Scelfo C, Mantagos IS. Mycoplasma Pneumoniae-Induced Rash and Mucosisis: A Longitudinal Perspective and Proposed Management Criteria. Am J Ophthalmol. 2020;219:351-356. doi: 10.1016/j.ajo.2020.06.010

17. Rokkas T, Niv Y, Malfertheiner P. A Network Meta-Analysis of Randomized Controlled Trials on the Treatment of Esino-philic Esophagitis in Adults and Children. J Clin Gastroenterol. 2021;55(5):440-4410. doi: 10.1097/MCG.0000000000003356

18. Dorinsky P, DePettrillo P, DeAngelis K, Trivedi R, Darken P, Gil len M. Relative Bioavailability of Budesonide/Glycopyrrolate/ Formoterol Fumarate Metered Dose Inhaler Administered With and Without a Spacer: Results of a Phase I, Randomized, Crossover Trial in Healthy Adults. Clin Ther. 2020;42(4):634-648. doi: 10.1016/j.clinthera.2020.02.012

19. Vizzarraga D, Torres-Puig S, Aparicio D, Pich QO. The Sialoglycan Binding Adhesins of Mycoplasma genitalium and Mycoplasma pneumonias. Trends Microbiol. 2021;29(6):477-481. doi: 10.1016/j.trendsmicrobio.2021.01.011

20. Venge P, Eriksson S, Paukkinen K. Blood biomarker algorithms for the diagnosis of mycoplasma pneumonias respiratory infections. J Im munol Methods. 2021;489:112908. doi: 10.1016/j.jim.2021.112908

21. Yang CF, Jeng MJ, Soong WJ, Lee YS, Tsao FC, Yang KB. Acute pathophysiologic effects of intratracheal instillation of budesonide and exogenous surfactant in a neonatal surfactant-depleted piglet model. Pediatr Neonatol. 2010;51(4):219-226. doi: 10.1186/1815-9752(2010)04-0023-3

22. Marraro GA, Luchetti M, Spada C, Galassini E, Giossi M, Piero AM. Selective medicated (normal saline and exogenous surfactant) bronchoalveolar lavage in severe aspiration syndrome in children. Pediatr Crit Care Med. 2007;8(5):476-81. doi: 10.1097/01.pcc.0000282158.09763.7c

23. Tan XZ, Wu SG, Zhang JH, Li XF, Gao PM, Wang Y. Clinical efficacy of porcine pulmonary surfactant combined with budesonide suspension intratracheal instillation in the treatment of neonatal meconium aspiration syndrome. Zhongguo Dang Dai Er Ke Za Zhi. 2016;18(12):1257-1241. doi: 10.7499/jzddke.2016.12.0008

24. Chu C, Lei X, Li Y, Luo Y, Ding Y, Zhou W, et al. High expression of miR-222-3p in children with Mycoplasma pneumoniae pneumonia. Ital J Pediatr. 2019;45(1):163. doi: 10.1186/s13052-019-0750-7

25. Su S, Li C, Zhao Y, Yu L, Wang Y, Wang Y, et al. Outbreak of KPC-2-Producing Klebsiella pneumoniae ST76 Isolates in an Intensive Care Unit and Neurosurgery Unit. Microb Drug Resist. 2020;26(9):1009-1018. doi: 10.1089/mdir.2019.0363

Authors’ Contributions: YL & XG: Designed this study and prepared this manuscript, and are responsible for the accuracy or integrity of the work. WY: Collected and analyzed clinical data. XW: Significantly revised this manuscript.